- Details
- Alicia Morgans speaks with Felix Feng about his pioneering work in prostate cancer, specifically focusing on the integration of artificial intelligence (AI) to enhance understanding of pathology. Dr. Feng emphasizes that AI technology is already here and is being utilized to leverage extensive information about prostate cancer to make better-personalized decisions regarding patient care. He highli...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss The Journal of Clinical Oncology publication entitled, "Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial." This trial evaluated the treatment effect of adding docetaxel to ADT + radiation therapy on the primary end point of overall...
|
- Details
- Eric Small presents a discussion on primary small cell prostate cancer and therapeutic approaches to consider in aggressive variant prostate cancer (AVPC) and small cell neuroendocrine prostate cancer (t-SCNC) patients. Biographies: Eric Small, MD, Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF, Pro...
|
- Details
- Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director of Dep...
|
- Details
- Rob Reiter and Alicia Morgans discuss the use of MRI and active surveillance in prostate cancer treatment. Dr. Reiter explains how MRI is used to improve proper patient selection for active surveillance. He also discusses how he was an early adopter of MRI and how he incorporates an MRI-guided biopsy program in his practice. In conclusion, Dr. Reiter and Dr. Morgans agree it’s important to note th...
|
- Details
- Matthew Cooperberg warmly welcomes Sanoj Punnen, to discuss the complexities surrounding the prediagnostic space for men with elevated PSA levels and the challenging decision of whether to pursue a biopsy. Dr. Punnen highlights the limitations of PSA as a screening tool, emphasizing the emerging role of liquid biopsy markers and MRI in this area. They both recognize the significance of integrating...
|
- Details
- Dan George discusses the Ironman study, a significant international registry aimed at enhancing outcomes for men with advanced prostate cancer. This cohort study, distinct from clinical trials, longitudinally tracks patients to identify unmet needs and intervention opportunities in practice settings, rather than trial environments. It focuses on two patient groups: those with de novo metastatic, c...
|
- Details
- Derya Tilki discusses the complexities of managing pathologic node-positive (pN1) disease in prostate cancer. Dr. Tilki highlights the increasing rates of patients with positive lymph nodes at radical prostatectomy and explores various postoperative management strategies, including observation, androgen deprivation therapy (ADT), and adjuvant radiation. She emphasizes the heterogeneity of pN1 dise...
|
- Details
- In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...
|
- Details
- Alexandra Sokolova joins Alicia Morgans to discuss her work on biochemical recurrent prostate cancer. Dr. Sokolova and her team at OHSU hypothesize that a combination of durvalumab and olaparib will result in a deeper remission, delay the need for ADT, and improve the quality of life for patients who have a shorter PSA doubling time and a higher risk of developing metastasis. Biographies: Alexandr...
|
